Table 3 New Phase II trials
From: Maintenance therapy in NSCLC: why? To whom? Which agent?
Trial/Author | Comparison | Comments | References |
|---|---|---|---|
NCT00867009 | Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab as Maintenance IIIB or IV Nonquamous NSCLC | ongoing, but not recruiting | [39] |
NCT00687297 | Vandetanib (ZD6474)n With Docetaxel and Carboplatin Followed by Placebo or Vandetanib as Maintenance in IIIb, IV or Recurrent NSCLC | ongoing, but not recruiting | [39] |
NCT01004250 | Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Nonsquamous Advanced NSCLC | currently recruiting | [39] |
NCT00425646 | Maintenance Strategy of Gleevce® (Imatinib Mesylate) and Bevacizumab in Advanced, Non-Squamous, NSCLC Following Completion of First-Line Chemotherapy With Bevacizumab | ongoing, but not recruiting | [39] |
NCT00766246 | Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV NSCLC | currently recruiting | [39] |